1,3-二辛酰甘油(C8:0) | 1429-66-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油脂
• 中文名称: 1,3-二辛酰甘油(C8:0)
• 中文别名: 1,3-二辛酰甘油
• 英文名称: 1,3-dicaprylin
• 英文别名: 2-hydroxypropane-1,3-diyl dioctanoate；1,3-dioctanoylglycerol；Dioctanoylglycerol；(2-hydroxy-3-octanoyloxypropyl) octanoate
• CAS: 1429-66-9
• 化学式: C₁₉H₃₆O₅
• 分子量: 344.492
• InChiKey: DMBAVJVECSKEPF-UHFFFAOYSA-N

物化性质

• 熔点：
  <4 °C
• 沸点：
  439.9±12.0 °C(Predicted)
• 密度：
  0.992±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）
• 物理描述：
  Solid
• 保留指数：
  2375.7

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  24
• 可旋转键数：
  18
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  72.8
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2915900090
• 储存条件：
  | -20°C |

反应信息

• 作为反应物：
  描述：

  1,3-二辛酰甘油(C8:0) 在 吡啶 作用下， 以 乙醚 、 氯仿 、 异丙醇 、 乙腈 为溶剂， 反应 1.0h， 生成 1,3-dioctanoylglycero-2-phosphocholine
  参考文献：
  名称：

  1,3-Diacylglycero-2-phosphocholines — synthesis, aggregation behaviour and properties as inhibitors of phospholipase D

  摘要：

  A series of 1,3-diacylglycero-2-phosphocholines (1,3-PCs) with acyl chain lengths of C-8-C-18 were synthesised by chemical introduction of the phosphocholine moiety into the regioisomerically pure 1,3-diacylglycerols, which were obtained from glycerol and the vinyl esters of fatty acid by means of lipase from Rhizomucor mihei. The I,3-PCs being regioisomers of the natural glycerophospholipids were studied with respect to their aggregation behaviour in the absence and in the presence of sodium dodecylsulfate (SDS) as well as their properties as substrates and inhibitors of phospholipase D (PLD) from cabbage. While the main structures of the pure 1,3-PCs were micelles (C-8), liposomes (C-10, C-12) or planar bilayers (C-14, C-16, C-18), the addition of SDS resulted in the formation of mixed micelles (C-8, C-10) and mixed liposomes (C-12, C-14, C-16, C-18). None of the 1,3-PCs was found to be hydrolysed by PLD, whereas all of them showed inhibitory properties in the standard assay for PLD. The inhibitory power was strongest with 1,3-didecanoylglycero-2-phosphocholine (IC50 = 43 mu M). (C) Elsevier Science Ireland Ltd. All rights reserved.

  DOI：

  10.1016/s0009-3084(99)00120-6
• 作为产物：
  描述：

  2-oxopropane-1,3-diyl dioctanoate 在 sodium tetrahydroborate 作用下， 以 四氢呋喃 、 水 、 苯 为溶剂， 以86%的产率得到1,3-二辛酰甘油(C8:0)
  参考文献：
  名称：

  肉桂酸酯类的新防晒霜：对甲氧基肉桂酸甘油酯的合成和酶水解评估。

  摘要：

  对甲氧基肉桂酸，1,3-二棕榈酰基-2-对甲氧基肉桂酰基-1,2,3-丙三醇和1,3-二辛酰基-2-对甲氧基肉桂酰基-1,2,3-丙三醇的甘油酯在试图增加直接性并减少此类防晒霜的最终不良影响。为了评估甘油酯是否可以对角质层中的脂肪酶水解具有更高的稳定性，在体外使用来自Rhizomucor miehei的商业真菌脂肪酶测定了水解速率。本文给出的结果表明，该甘油酯具有与肉桂酸酯类防晒霜相似的λ（max）和ε值。酯1，3-二棕榈酰基-2-对甲氧基肉桂酰基-1,2,3-丙三醇在体外的脂肪酶水解速率比市售防晒霜2-乙基己基-对甲氧基肉桂酸酯（烷基酯）低2.8倍。

  DOI：

  10.1016/j.ejps.2005.01.018

文献信息

• [EN] LIPID PRODRUGS OF JAK INHIBITORS AND USES THEREOF<br/>[FR] PROMÉDICAMENTS LIPIDIQUES D'INHIBITEURS DE JAK ET LEURS UTILISATIONS
  申请人：PURETECH LYT INC

  公开号：WO2020176859A1

  公开（公告）日：2020-09-03

  The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, and methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

  本发明提供了淋巴系统定向脂质前药，其药物组成物，生产这种前药和组成物的方法，以及改善作为脂质前药一部分的治疗剂的生物利用度或其他性质的方法。本发明还提供了治疗疾病、紊乱或状况的方法，例如本文所披露的那些，包括向需要的患者施用所披露的脂质前药或其药物组成物。
• Chemoenzymatic synthesis of structured triacylglycerols
  作者：Arnar Halldorsson、Carlos D Magnusson、Gudmundur G Haraldsson

  DOI：10.1016/s0040-4039(01)01598-2

  日期：2001.10

  Six regioisomerically pure structured triacylglycerols possessing a medium-chain fatty acid (C8, C10 or C12) at the primary positions and pure eicosapentaenoic acid or docosahexaenoic acid at the secondary position of the glycerol moiety were prepared in two steps by a chemoenzymatic approach using lipase.

  通过化学酶法分两个步骤制备了六种区域异构纯的结构三酰甘油，它们在主要位置具有中链脂肪酸（C 8，C 10或C 12），在次要位置具有纯二十碳五烯酸或二十二碳六烯酸。使用脂肪酶。
• Sulfated diglyceride derivatives, salts thereof, and processes for their preparation
  申请人：Rosen J. Milton

  公开号：US20060167298A1

  公开（公告）日：2006-07-27

  The present invention relates to novel sulfated derivatives of disubstituted glycerides, and to methods for their preparation. In some embodiments, the present invention provides compounds having the Formula Ia or Ib: wherein the constituent variables are as defined herein.

  本发明涉及新型磺酸化的二取代甘油酯衍生物，以及其制备方法。在某些实施例中，本发明提供具有化学式Ia或Ib的化合物： 其中组分变量如本文所定义。
• Radical chlorinations of triglycerides
  作者：Philip E. Sonnet、Stanley Osman

  DOI：10.1007/bf02541098

  日期：1995.3

  Several triglycerides were synthesized with an iodoaroyl group. Intramolecular radical chain transfer chlorinations were conducted that resulted in the associated pair of fatty acids of the triglyceride becoming chlorinated. The distribution of monochlorinated species was similar to that obtained by direct radical chlorination of the relevant fatty acid methyl esters. Functionalization was, as expected, away from the carboxylate group but gave no indication that either alignment of chains or the constraints of an intramolecular process could limit the manifold of products of the reaction. To gauge the effect on halogenation of a structure, bearing more than one electron‐withdrawing group, methyl oleate was converted to thebis trifluoroacetate of methyl 9,10‐dihydroxystearate. No products of chlorination on carbons 2–8 were observed.

  摘要 合成了几种带有碘代芳酰基的甘油三酯。通过分子内自由基链转移氯化反应，使甘油三酯中相关的一对脂肪酸发生氯化。单氯化物种的分布与相关脂肪酸甲酯直接自由基氯化的结果相似。正如预期的那样，官能化远离羧酸基，但没有迹象表明链的排列或分子内过程的限制会限制反应产物的多样性。为了衡量含有一个以上电子抽取基团的结构对卤化的影响，将油酸甲酯转化为 9,10-二羟基硬脂酸甲酯的双三氟乙酸盐。在碳 2 至 8 上没有观察到氯化产物。
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS<br/>[FR] COMPOSITIONS ET PROCÉDÉS DE TRAITEMENT D'INFECTIONS FONGIQUES
  申请人：CELLIX BIO PRIVATE LTD

  公开号：WO2018096497A1

  公开（公告）日：2018-05-31

  The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX or Formula X and, the methods for the treatment of fungal infections may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of fungal infections.

  该发明涉及化合物或其药用可接受的多型体、溶剂合物、对映体、立体异构体及其水合物。包括有效量的I式、II式、III式、IV式、V式、VI式、VII式、VIII式、IX式或X式化合物的药物组合物，以及用于治疗真菌感染的方法可以制备为口服、颊部、直肠、局部、经皮、经粘膜、含片、喷雾、静脉注射、口服溶液、颊粘膜层片剂、肠外给药、糖浆或注射剂。这些组合物可用于治疗真菌感染。